Researchers examined a random sample of health insurance claim records of 16 million patients in the United States between 2006 and 2020 for use of semaglutide drugs.
A new report from ISMP Canada shares what doctors, pharmacists, anaesthesiologists and others should do about the increased risk of aspiration after anesthesia for people taking GLP-1 receptor agonists like semaglutide.
Public formularies are starting to cover biosimilar insulins instead of their reference biologic drugs and it is predicted that this will save millions of dollars annually.
